March 15 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO :
* Reports preliminary unaudited fourth quarter 2015 financial information
* Q4 revenue $2.8 billion versus I/B/E/S view $2.75 billion
* Sees Q1 2016 adjusted non-GAAP earnings per share $1.30 to $1.55
* Q4 GAAP loss per share $0.98
* Sees Q1 2016 revenue $2.3 billion to $2.4 billion
* Q4 earnings per share view $2.61 -- Thomson Reuters I/B/E/S
* Source text for Eikon ID:nCNW19z51a
* Further company coverage VRX.TO